The Enanta Pharmaceuticals, Inc. (ENTA) Position Lowered by Alliancebernstein L.P.

The Enanta Pharmaceuticals, Inc. (ENTA) Position Lowered by Alliancebernstein L.P.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Mason Street Advisors LLC boosted its position in shares of Enanta Pharmaceuticals by 7.0% in the first quarter. Mason Street Advisors LLC now owns 3,249 shares of the biotechnology company’s stock worth $100,000 after buying an additional 212 shares during the period. State Board of Administration of Florida Retirement System bought a new position in shares of Enanta Pharmaceuticals during the fourth quarter worth about $204,000. Thrivent Financial for Lutherans bought a new position in shares of Enanta Pharmaceuticals during the fourth quarter worth about $250,000. A.R.T. Advisors LLC bought a new position in shares of Enanta Pharmaceuticals during the fourth quarter worth about $268,000. Finally, HPM Partners LLC bought a new position in shares of Enanta Pharmaceuticals during the first quarter worth about $278,000. 66.42% of the stock is owned by institutional investors.

Alliancebernstein L.P. reduced its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 42.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 75,910 shares of the biotechnology company’s stock after selling 56,150 shares during the period. Alliancebernstein L.P. owned 0.40% of Enanta Pharmaceuticals worth $2,338,000 as of its most recent SEC filing.

Shares of Enanta Pharmaceuticals, Inc. (ENTA) traded up 3.14% during mid-day trading on Wednesday, reaching $39.71. 447,390 shares of the company were exchanged. Enanta Pharmaceuticals, Inc. has a 12 month low of $21.00 and a 12 month high of $40.41. The company’s 50 day moving average price is $36.29 and its 200 day moving average price is $32.18. The firm’s market capitalization is $757.79 million.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, May 8th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.38) by $0.10. Enanta Pharmaceuticals had a negative net margin of 28.68% and a negative return on equity of 4.94%. The business had revenue of $9 million for the quarter, compared to analyst estimates of $9.19 million. During the same quarter in the previous year, the business earned ($0.09) earnings per share. The firm’s revenue was down 30.8% compared to the same quarter last year.

ENTA has been the subject of a number of recent research reports. Zacks Investment Research cut shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, May 12th. ValuEngine raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. BidaskClub cut shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. Finally, JMP Securities raised shares of Enanta Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $40.00 price objective for the company in a research note on Tuesday, July 11th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $30.75.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Related posts

Leave a Comment